Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8598133
Methods for treating pain
granted -
US 8598316
Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
granted -
US 8597946
Enhanced dendritic cells for cancer immunotherapy
granted -
US 8597616
Dry powder drug delivery formulations, methods of use, and devices therefore
granted -
US 8592384
Micro-RNA's that regulate muscle cells
granted -
US 8586308
Genetic markers of mental illness
granted -
US 8586553
Therapies for cancer using RLIP76
granted -
US 8586363
TAL effector-mediated DNA modification
granted -
US 8586291
Mutations in the Bcr-Abl tyrosine kinase associated with resistance to ST1-571
granted -
US 8586046
Methods and compositions for mycoplasma pneumoniae exotoxins
granted -
US 8586626
Metabolites of wortmannin analogs and methods of using the same
granted -
US 8580845
Functionalized expanded porphyrins
granted -
US 8580852
2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides
granted -
US 8580921
Protein nanorings
granted -
US 8580844
Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
granted -
US 8580738
Methods for treatment of reperfusion injury and other cardiac conditions
granted -
US 8580773
Small-molecule inhibitors of the androgen receptor
granted -
US 8580290
Heparosan-based biomaterials and coatings and methods of production and use thereof
granted -
US 8580245
Compositions and methods for treating and preventing cardiomyopathy and heart disease
granted -
US 8580249
Cell therapy for the treatment of lysosomal storage disorders
granted -
US 8580263
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
granted -
US 8575170
Flurbiprofen analogs and methods of use in treating cancer
granted -
US 8575319
Cleavable vaccine compositions and uses thereof and methods of making and using the same
granted -
US 8575359
Acid-sensitive linkers for drug delivery
granted -
US 8569242
Method of treating degenerative disorders of the nervous system
granted -
US 8568769
Particle-containing complex porous materials
granted -
US 8569225
Targeting complement factor H for treatment of diseases
granted -
US 8562993
Methods for treating GI syndrome and graft versus host disease
granted -
US 8563595
Treatment of cancer with complex organic-inorganic pigment compositions
granted -
US 8563028
Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication
granted -
US 8562944
PAA nanoparticles for enhancement of tumor imaging
granted -
US 8562948
Somatostatin analogs with inhibitory activity to growth hormone release
granted -
US 8563692
Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
granted -
US 8563515
Tight junction protein modulators and uses thereof
granted -
US 8563022
Particles for cell targeting
granted -
US 8563001
Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
granted -
US 8562949
Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
granted -
US 8557812
Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
granted -
US 8557295
Use of cellular extracts for skin rejuvenation
granted -
US 8557969
Compositions and methods for regulating cardiac performance
granted -
US 8557245
Methods for treating bone cancer by administering a nerve growth factor antagonist antibody
granted -
US 8557764
Methods of modulating immune function
granted -
US 8552018
Substituted tricyclic compounds as protein kinase inhibitors
granted -
US 8552167
Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
granted -
US 8552150
MART-1 T cell receptors
granted -
US 8551526
Preparation of drug particles using evaporation precipitation into aqueous solutions
granted -
US 8551467
Replenishment and enrichment of ocular surface lubrication
granted -
US 8552067
Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory